Research use only · Multi-region fulfillment · Support-assisted ordering
VestaResearch Supply
Zexipag 200mg Tablets | 100-Count | PAZOPANIB
Pharma

Zexipag 200mg Tablets | 100-Count | PAZOPANIB

$230

In stock

For in vitro laboratory research only. Not for human or veterinary consumption.

India Warehouse PAZOPANIB — 200mg per tablet, 100-count pack. Multi-kinase inhibitor for advanced renal cell carcinoma and advanced soft tissue sarcoma after prior chemotherapy. Key warning: Hepatotoxicity monitoring mandatory — LFTs at baseline, then 4-8 weekly. Blood pressure monitoring from day 1. Antihypertensive treatment often required. QT prolongation monitoring.

SKU
VES-002564-ZEXIPAG-200MG-100TAB
Format
N/A
Use
Laboratory research only
Ask on Telegram

What is Zexipag 200mg (PAZOPANIB)?

Multi-kinase inhibitor for advanced renal cell carcinoma and advanced soft tissue sarcoma after prior chemotherapy.

How it Works

Inhibits VEGFR-1, -2, -3, PDGFR-alpha and -beta, and KIT — blocks tumor angiogenesis and proliferative signaling.

Quick Specs

Form
Oral tablets — pre-dosed
Active Ingredient
PAZOPANIB
Dose per Tablet
200MG
Pack Size
10×10 (100 tablets)
Storage
Room temperature (15–25°C), cool dry place
Shelf Life
2–3 years (properly stored)

Common Side Effects

Hypertension (very common), hepatotoxicity, diarrhea, hair color changes (depigmentation), nausea, fatigue, QT prolongation.

Safety Warnings

Hepatotoxicity monitoring mandatory — LFTs at baseline, then 4-8 weekly. Blood pressure monitoring from day 1. Antihypertensive treatment often required. QT prolongation monitoring. International shipping: 7–14 days

Research use only

This material is supplied strictly for in vitro laboratory research. It is not intended for human or veterinary consumption, diagnosis, treatment, or household use.